Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 10/20 | 0.37 |
| ▸ | DNM1L | O00429 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3018488 | 0.93 | DRD2 (0.41) | DRD2HTR2AHTR2CKCNH2CTSS | |
| SCHEMBL3017397 | 0.90 | DRD2 (0.42) | DRD2HTR2AHTR2CKCNH2CTSS | |
| SCHEMBL3016424 | 0.88 | DRD2 (0.42) | DRD2HTR2AHTR2CKCNH2CTSS | |
| SCHEMBL3016702 | 0.88 | DRD2 (0.42) | DRD2HTR2AHTR2CKCNH2CTSS | |
| SCHEMBL3008762 | 0.88 | DRD2 (0.41) | DRD2HTR2AHTR2CKCNH2CTSS | |
| SCHEMBL3011738 | 0.87 | DRD2 (0.41) | DRD2HTR2AHTR2CKCNH2CTSS | |
| SCHEMBL3003859 | 0.87 | DRD2 (0.41) | DRD2HTR2AHTR2CKCNH2CTSS | |
| SCHEMBL3004391 | 0.86 | CTSS (0.40) | CTSSDNM1LSMN1; SMN2 | |
| SCHEMBL3015218 | 0.86 | CTSS (0.41) | CTSSDNM1LSMN1; SMN2 | |
| SCHEMBL3011781 | 0.86 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | SMN1; SMN2, HTT, SNCA | DRD2 573/4885HTR2A 752/4885HTR2C 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.